Inovio Pharmaceuticals, Inc. (INO) along with Korean partner GeneOne Life Science announced that it has dosed the first patient in a phase I study, evaluating its hepatitis C vaccine GLS-6150 to boost immunity in patients. Both companies are jointly developing the world’s first vaccine to prevent hepatitis C infection.

Korean pharma company GeneOne Life Science has already started enrolling patients in South Korea and will be responsible for conducting and funding the phase I trial to evaluate the vaccine in patients, previously treated and cured of the virus.

The open label phase I study will enroll 24 subjects, who showed a sustained virologic response (SVR) after undergoing the treatment for hepatitis C. Patients will be administered with one of two doses of vaccine, 1 or 2 mg, intradermally followed by electroporation with Cellectra-3P device. The company expects to report data from the program in 2019.

Read more…https://www.zacks.com/stock/news/321354/inovio-ino-initiates-phase-i-study-on-hepatitis-c-vaccine